Post-earnings recap
Reported
Thu, Feb 26, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Sarepta Therapeutics reported a larger-than-expected loss per share, which contributed to a 7.81% decline in its stock price. The lack of revenue data and forward guidance left investors uncertain about the company's future performance. Management's focus on clinical trials suggests they are prioritizing long-term goals over short-term financial results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.94 | N/A | -13.25% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding the current market conditions. They emphasized their commitment to advancing their pipeline despite the financial results.
Management did not provide specific guidance for future quarters.
The company is focusing on ongoing clinical trials and regulatory processes.